In line with the pilot tolerability study (Supplementary Fig. S5f), the surviving cells in the A5/158-vc-MMAE–treated MG-63 tumors retain Endo180 expression as monitored by IHC and RT-qPCR (Fig. 5G and H). This evidence concerns the gene MRC2 and myasthenia gravis.